As of June 30, 2025, Merus (MRUS) had $892 million cash, cash equivalents and marketable securities. Based on the Company’s current operating plan, the existing cash, cash equivalents and marketable securities are expected to fund Merus’ operations at least into 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for HNSCC Treatment
- Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study
- Truist biotech analyst holds an analyst/industry conference call
- Merus N.V.’s MCLA-129 Study: A Potential Game-Changer in Cancer Treatment
- Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know